NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
83.40
+0.36 (+0.44%)
As of 10:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close83.04
Open83.26
Bid83.45 x 900
Ask83.47 x 1800
Day's Range83.20 - 83.50
52 Week Range72.30 - 94.19
Volume293,559
Avg. Volume1,808,295
Market Cap194.976B
Beta0.86
PE Ratio (TTM)24.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.98 (3.85%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges
    Market Realist20 minutes ago

    Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges

    Mylan (MYL) made a downward revision to its fiscal 2018 guidance during its second-quarter earnings release on August 8. A major factor driving down the company’s performance was lower North America sales due to volume declines in the company’s existing products. Due to the impact of “turbulence in the U.S. and the disturbing trends regarding access to complex products,” Mylan lowered its fiscal 2018 guidance during its second-quarter earnings release on August 8.

  • Mylan Has a Strong Balance Sheet despite Weak Q2 Performance
    Market Realist2 hours ago

    Mylan Has a Strong Balance Sheet despite Weak Q2 Performance

    Mylan (MYL) ended the second quarter with cash and cash equivalents of $330.2 million. This compared to the net cash provided by operating activities of $1.02 billion available to the company by the end of the fiscal second quarter of 2017. For the six months ended June 30, Mylan’s adjusted free cash flows were $1.3 billion, up ~22% YoY (year-over-year).

  • Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
    Market Realist3 days ago

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

  • Array BioPharma Missed Sales Estimates for Q4 2018
    Market Realist3 days ago

    Array BioPharma Missed Sales Estimates for Q4 2018

    Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million. The rise was mainly due to earned milestones, new and expanded collaborations, and an increase in expense reimbursements related to the Beacon CRC trial. Pierre Fabre, a French pharmaceutical company, has an agreement with Array Biopharma to fund 40% of the cost of the Beacon CRC trial.

  • Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics
    Market Realist3 days ago

    Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics

    Mylan reported its second-quarter results on August 8. Mylan had completed a $1.0 billion share repurchase program at the beginning of 2018, the benefits of which are reflected in its adjusted EPS growth. In the second quarter, Mylan’s gross profit fell ~40% YoY to $962.5 million.

  • FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
    Market Realist4 days ago

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.

  • MarketWatch4 days ago

    FDA approves first rival generic EpiPen, sending Teva shares up 6%

    Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. (TEVA) surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector. Shares of Mylan (MYL) , which sells the EpiPen and a cheaper authorized generic version, slumped 0.5% in heavy trade, while rivals Amneal Pharmaceuticals Inc. (AMRX) and Adamis Pharmaceuticals Corp. (ADMP) had shares drop 3% and 7.5% respectively.

  • Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?
    Market Realist4 days ago

    Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?

    The company missed Wall Street analysts’ sales estimate of $2.96 billion for the second quarter. The company’s sales have seen YoY declines for the last three quarters. The company is facing intense competition for its EpiPen injectable and the challenging US market dynamics pressuring pricing.

  • MYL Stock Down ~3% since Its Q2 2018 Results on August 8
    Market Realist4 days ago

    MYL Stock Down ~3% since Its Q2 2018 Results on August 8

    The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $29.39 on August 15, 2017. Currently, MYL stock is trading above its 50-day moving average of $36.80 but below its 200-day moving average of $39.52. On August 8, MYL stock had declined as much as 7.2% on disappointing second-quarter results that missed analysts’ estimates.

  • Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
    Market Realist4 days ago

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Myan (MYL) reported its second-quarter earnings on August 8. For brief highlights, please read Mylan Stock Falls on Q2 Results: Misses Estimates, Cuts Outlook. Following its weak second-quarter performance, multiple brokerages updated their recommendations and target prices on MYL stock, which we’ll discuss in this article.

  • Market Exclusive4 days ago

    Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail

    Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.

  • A Performance Overview of Bausch + Lomb
    Market Realist5 days ago

    A Performance Overview of Bausch + Lomb

    Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter compared to $1.22 billion in the second quarter of 2017, reflecting a ~1% YoY (year-over-year) fall. However, Bausch + Lomb witnessed ~4% YoY organic growth in the second quarter.

  • Three expansions, 923 jobs: Durham County approves incentives packages
    American City Business Journals6 days ago

    Three expansions, 923 jobs: Durham County approves incentives packages

    Durham County approved incentives worth nearly $450,000 combined Monday, including a package solidifying gene therapy firm AveXis’ 200-job expansion in the Triangle.

  • Array BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Array BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript

    ARRY earnings call for the period ending June 30, 2018.

  • Zacks6 days ago

    Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

    Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

  • Pfizer Expected to Report Robust EPS Rise in Fiscal 2018
    Market Realist6 days ago

    Pfizer Expected to Report Robust EPS Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.

  • What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
    Market Realist6 days ago

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

  • Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
    Market Realist6 days ago

    Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

  • GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
    Market Realist6 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.

  • Novartis recruits new compliance head from Siemens after ethics stumbles
    Reuters6 days ago

    Novartis recruits new compliance head from Siemens after ethics stumbles

    Novartis (NOVN.S) has recruited a new chief ethics officer from Siemens (SIEGn.DE) after costly bribery scandals and a disputed $1.2 million (938,673.3 pounds) contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake. Novartis said on Tuesday it had hired Klaus Moosmayer, 49, from Siemens, where he spent more than a decade helping oversee the German engineering company's efforts to build its compliance system after several of its own bribery scandals. Novartis Chief Executive Vas Narasimhan, promoted on Feb. 1 to lead the Basel-based company, has promised to boost its reputation following settlements or fines in corruption cases in China, South Korea and the United States.

  • Novartis recruits new compliance head from Siemens after ethics stumbles
    Reuters6 days ago

    Novartis recruits new compliance head from Siemens after ethics stumbles

    Novartis (NOVN.S) has recruited a new chief ethics officer from Siemens (SIEGn.DE) after costly bribery scandals and a disputed $1.2 million contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake. Novartis said on Tuesday it had hired Klaus Moosmayer, 49, from Siemens, where he spent more than a decade helping oversee the German engineering company's efforts to build its compliance system after several of its own bribery scandals. Novartis Chief Executive Vas Narasimhan, promoted on Feb. 1 to lead the Basel-based company, has promised to boost its reputation following settlements or fines in corruption cases in China, South Korea and the United States.

  • OPKO Health Expects Its Loss per Share to Shrink This Year
    Market Realist7 days ago

    OPKO Health Expects Its Loss per Share to Shrink This Year

    In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million. The company has projected a single-digit effective tax rate for Q3 2018. In fiscal 2018, analysts expect OPKO Health’s adjusted diluted EPS to rise ~51.0% to -$0.24, while peers Novartis (NVS), Merck (MRK), and Regeneron (REGN) are expected to report adjusted diluted EPS of approximately $5.20, $2.60, and $20.40, respectively.

  • Benzinga7 days ago

    Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

    Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO  at $18 per share. The Analysts ...

  • OPKO Health’s Q3 2018 Revenue Expectations
    Market Realist7 days ago

    OPKO Health’s Q3 2018 Revenue Expectations

    In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes. Meanwhile, the company expects product revenue of $28 million–$32 million, and Rayaldee revenue of $5.7 million–$6.5 million.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist7 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...